antimicrobi
prophylaxi
start
condit
regimen
consist
acyclovir
time
day
levofloxacin
mgday
cotrimoxazol
tablet
per
day
day
tablet
everi
day
resum
hematolog
reconstitut
antifung
prophylaxi
perform
echinocandin
either
caspofungin
micafungin
mgday
day
itraconazol
mgday
iv
administ
unless
contraind
otherwis
echinocandin
maintain
septemb
echinocandin
maintain
patient
acyclovir
levofloxacin
antifung
prophylaxi
administ
engraft
occur
twice
weekli
blood
polymeras
chain
reaction
pcr
cmv
monitor
start
day
day
weekli
day
clinic
indic
weekli
viru
ebv
monitor
pcr
start
day
day
clinic
indic
test
perform
whenev
indic
alon
combin
aminoglycosid
administ
empir
therapi
febril
neutropenia
unless
previou
colon
resist
bacteria
document
case
appropri
antibacteri
agent
deliv
true
suspect
bacteri
infect
occur
except
pneumonia
linezolid
ad
combin
antibacteri
drug
preemptiv
therapi
cmv
infectionreactiv
intraven
ganciclovir
wherea
foscarnet
administ
patient
aplasia
ebv
reactiv
hemorrhag
cystiti
treat
rituximab
cidofovir
respect
threshold
cmv
viremia
initi
therapi
copiesml
threshold
ebv
viremia
copiesml
analysi
circul
lymphocyt
perform
regular
interv
whenev
avail
day
everi
month
afterward
follow
monoclon
antibodi
combin
use
beckman
coulter
fullerton
california
usa
quantifi
b
nk
cell
compart
differ
time
point
studi
categor
variabl
express
absolut
number
respect
percentag
continu
variabl
median
respect
rang
cumul
incid
viral
bacteri
fungal
infect
calcul
use
compet
risk
analysi
start
day
day
first
infect
death
consid
compet
event
infect
incid
also
express
time
period
within
year
transplant
interv
defin
follow
day
owe
pauciti
late
event
data
beyond
day
collect
singularli
classifi
accord
pathogen
group
neutrophil
engraft
defin
first
consecut
day
persist
count
platelet
engraft
defin
first
consecut
day
persist
count
http
method
use
comput
overal
surviv
cumul
incid
trm
acut
chronic
gvhd
calcul
use
compet
risk
analysi
death
document
infect
defin
death
test
use
compar
incid
infect
flow
cytometri
result
engraft
rate
patient
median
day
rang
day
rang
neutrophil
platelet
recoveri
respect
four
patient
die
engraft
day
sepsi
multiorgan
failur
progress
diseas
bacteri
pneumonia
respect
present
primari
graft
failur
aliv
last
autolog
reconstitut
day
cumul
incid
acut
grade
gvhd
ci
ci
respect
chronic
gvhd
ci
overal
surviv
ci
trm
ci
patient
relaps
progress
death
occur
day
bacteri
pneumonia
sepsi
cmv
pneumonia
pneumonia
jc
progress
multifoc
leukoencephalopathi
caus
trm
heart
failur
n
secondari
malign
n
myelodysplast
syndrom
n
esophag
cancer
multiorgan
failur
n
thrombot
microangiopathi
n
acut
hepat
n
last
patient
aliv
complet
remiss
immunophenotyp
analysi
reveal
progress
increas
lymphocyt
subset
count
day
later
time
point
found
trend
toward
less
viral
infect
incid
among
patient
total
lymphocyt
count
day
hazard
ratio
p
associ
observ
lymphocyt
subset
number
patient
analyz
shown
figur
present
analysi
describ
infecti
complic
unmanipul
replet
use
cy
consecut
patient
found
asid
high
incid
viral
infectionsreactiv
especi
earli
period
quit
low
incid
late
bacteri
infect
togeth
low
incid
ifi
day
event
overal
observ
present
find
confirm
infecti
profil
better
replet
vs
deplet
lower
incid
infect
observ
day
may
reflect
partial
quit
effect
restor
antimicrobi
immun
period
type
importantli
low
rate
chronic
gvhd
seen
cohort
like
contribut
phenomenon
chronic
gvhd
known
major
risk
factor
late
morbid
mortal
nevertheless
found
unexpect
trm
incid
higher
origin
report
cy
may
result
inclus
patient
advanc
diseas
program
center
concern
viral
infect
result
line
previou
public
set
replet
haploident
transplant
ciurea
et
al
report
within
first
month
transplant
vs
day
hand
raiola
et
al
found
patient
present
viral
infect
first
year
cmv
reactiv
found
compar
report
similar
haploident
set
slightli
higher
incid
found
may
explain
longer
seri
cystiti
rate
lower
report
myeloabl
set
like
differ
condit
regimen
cohort
although
role
play
differ
gvhd
prophylaxi
exclud
inde
bk
viru
nephropathi
found
frequent
associ
tacrolimu
cyclosporin
recipi
kidney
allograft
quarter
patient
receiv
cyclosporin
gvhd
prophylaxi
interestingli
confirm
lack
lymphoprolif
disord
recent
report
also
kanakri
et
al
found
incid
fungal
infect
none
fatal
import
note
fatal
episod
fungal
infect
among
major
limit
toxic
associ
deplet
exclud
role
play
use
prophylaxi
marrow
aplasia
although
difficult
draw
definit
conclus
owe
lack
true
control
arm
studi
low
number
ifi
note
observ
ifi
month
transplant
concern
bacteri
infect
may
explain
low
preval
late
bacteri
infect
ie
beyond
year
surpris
incid
chronic
gvhd
fact
risk
bacteri
event
remain
low
absenc
late
immunosuppress
therapi
median
month
observ
late
bacteri
event
total
patient
least
year
observ
last
observ
day
month
inform
argu
favor
fact
give
replet
graft
without
deep
vivo
ie
globulin
alemtuzumab
cy
allow
satisfactori
infecti
profil
transplant
cy
permit
naiv
memori
cell
reconstitut
immun
system
later
enabl
patient
protect
late
infecti
event
mechan
probabl
also
explain
high
viral
reactiv
incid
found
first
month
owe
low
number
adopt
transfer
memori
cell
earli
phase
transplant
lugli
e
et
al
unpublish
data
acknowledg
potenti
select
bia
may
present
studi
exclud
possibl
late
infect
captur
incomplet
report
howev
patient
follow
institut
therefor
unlik
clinic
relev
infecti
complic
miss
moreov
diagnost
procedur
prophylact
measur
similar
patient
thu
contribut
accuraci
diagnosi
infecti
event
conclus
present
data
consecut
patient
receiv
replet
cy
confirm
high
rate
viral
infect
day
lower
incid
infect
afterward
suggest
satisfactori
although
immun
reconstitut
type
transplant
futur
comparison
haploident
platform
andor
altern
stem
cell
sourc
ie
cord
blood
well
investig
novel
strategi
transfer
immun
warrant
furthermor
present
data
may
provid
use
inform
attempt
improv
control
infect
adequ
prophylaxi
andor
antimicrobi
therapi
earli
period
use
emerg
transplant
platform
